
    
      This is a single center, open-label, 2-period crossover study. The study consists of a
      screening visit followed by a treatment period comprising 2 treatment visits. The treatment
      period visits will be separated by a 4 to 14-day washout period. Eligible patients will be
      kept overnight prior to each treatment period.
    
  